Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA

Executive Summary

The European Medicines Evaluation Agency approved four biological products in 1999 that have not yet been licensed by FDA.

You may also be interested in...

Wyeth Prevenar Approval Expected By End of February

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.

Biologicals Approved In 1999

Product.......... Humate-P (S, V) Ingredient....... Antihemophilic factor/von Willebrand factor complex (human) Sponsor.......... Centeon Pharma GmbH Indication....... New indication for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate Date Approved.... 4/1/1999 Application No... 96-1099 Footnote......... Standard review; Orphan drug

Novo's NovoRapid Has 10-20 Min. Onset Of Action - EU Labeling

Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts